Login
Super Investors BIOS Capital Management, LP
BC

BIOS Capital Management, LP

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$34.2M
Positions
6
Quarter ended
September 30, 2026
Filed
November 13, 2026

Reported portfolio value by quarter (8 quarters reported)

$94.1M $34.2M
Q4 24 Q2 25 Q4 25 Q2 26 Q3 26

$94.1M in Q4 2024 → $34.2M now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Opus Genetics Inc 52.2% Unchanged 3,683,429 $17.8M
Actuate Therapeutics Inc 22.9% Unchanged 10,049,996 $7.84M
Cognition Therapeutics Inc 16.9% Unchanged 6,000,000 $5.76M
Rein Therapeutics Inc 7.0% Unchanged 2,982,375 $2.4M
Lantern Pharma Inc 0.7% Trimmed 5.4% 235,895 $238K
In8bio Inc 0.3% Unchanged 80,957 $108K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 7 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 13, 2026

Company Action Shares changed Value of change % of portfolio
Lantern Pharma Inc Trimmed −13,502 −$13.6K 0.7%

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Lantern Pharma Inc Trimmed −615,038 −$2.56M 2.5%
Rein Therapeutics Inc Added +1,000,000 +$1.04M 7.4%
In8bio Inc Trimmed −86,848 −$122K 0.3%

Q1 2026

quarter ended March 31, 2026 · filed May 13, 2026

Company Action Shares changed Value of change % of portfolio
Rein Therapeutics Inc Added +291,624 +$379K 4.9%
Lantern Pharma Inc Trimmed −145,072 −$199K 2.2%
In8bio Inc Trimmed −85,612 −$127K 0.5%

Q4 2025

quarter ended December 31, 2025 · filed February 13, 2026

Company Action Shares changed Value of change % of portfolio
In8bio Inc Exited −286,664 −$622K —
In8bio Inc New +253,417 +$593K 0.7%
Lantern Pharma Inc Trimmed −6,208 −$18.8K 3.7%

Q3 2025

quarter ended September 30, 2025 · filed November 12, 2025

Company Action Shares changed Value of change % of portfolio
Actuate Therapeutics Inc Added +84,917 +$568K 75.6%
Lantern Pharma Inc Trimmed −60,237 −$262K 5.0%

Q2 2025

quarter ended June 30, 2025 · filed August 12, 2025

Company Action Shares changed Value of change % of portfolio
In8bio Inc Trimmed −8,313,337 −$17.4M 0.8%
Opus Genetics Inc Added +2,688,180 +$2.53M 4.8%
Actuate Therapeutics Inc Added +71,428 +$436K 83.9%
Lantern Pharma Inc Trimmed −131,757 −$416K 4.7%

Q1 2025

quarter ended March 31, 2025 · filed May 14, 2025

No position changes this quarter.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support